Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SPArticle Published on 2022-10-132022-11-16 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, [키워드] “real world” study. Analysis Brazil calculated ChAdOx1 clinical trial comparable Control Coverage COVID-19 COVID-19 disease COVID-19 pandemic death Delta delta variant demographics dose Effectiveness Efficacy eligible first dose Gamma Hospitalization individual initiated Lineage material municipality offered PCR test PCR tests positive raise reduced reported sequenced severe disease severity state Strains Study design symptomatic infection Symptoms unique vaccinated individual vaccinated individuals vaccination Vaccine vaccine dose Vaccines variant variants of concern variants of SARS-CoV-2 [DOI] 10.3389/fpubh.2022.1016402 PMC 바로가기
Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritisArticle Published on 2022-10-122022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제, [키워드] addition age anti-CD20 therapy anti-S anti-S antibody anti-SARS-CoV-2 antibodies antibody Antibody Response BNT162b2 cell-mediated response Cellular immune response cellular immune responses ChAdOx1 Concentration Corona covariate adjustment COVID-19 COVID-19 vaccine declined dependent on DMARD (disease-modifying antirheumatic drug treatment) domains dose enrolled Factor healthy controls humoral IL-6 inhibitor immune response Infection inhibited investigated IQR magnitude median time mRNA-1273 Patient patients patients treated peptides positive patient reduced respiratory rheumatoid arthritis RNA RNA vaccine SARS-CoV-2 significant effect significantly Specific specific antibodies specific antibody subject T-cell T-cell Response targeted therapy the healthy the interferon the SARS-CoV-2 the vaccine therapy vaccination vaccination. Vaccine variables was measured were infected [DOI] 10.3389/fimmu.2022.960001 PMC 바로가기
Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in SpainArticle Published on 2022-10-072022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 진단, [키워드] antibody BNT162b2 booster vaccinations carried cellular Cellular immune response cellular immunity ChAdOx1 COVID-19 COVID-19 vaccination dose elimination half-life Follow-up healthcare worker Heterologous humoral Immunity individual infected individual inoculated mRNA-1273 naïve Naturally participant preserved Prospective Study receiving reported robust SARS-CoV-2 spike second dose single dose Spain T cell uninfected university vaccination Vaccine Validity [DOI] 10.1038/s41598-022-19537-2 PMC 바로가기
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccinationArticle Published on 2022-10-042022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] administration Adverse adverse effect anti-RBD Anti-RBD IgG antibody Antibody Response Arm ARMS binding domain BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 comparable Concentration conducted CoronaVac country COVID COVID vaccine COVID-19 COVID-19 vaccine COVID-19 vaccines dose Effect Effects eligible exploratory first dose fractional dose vaccination Frame Heterologous heterologous regimen highest homologous IgG immunogenic implication IMPROVE Intradermal intradermal vaccination intradermal vaccine intramuscular intramuscular vaccination less lowest of BNT162b2 Omicron variant pilot study Population Protein regimen regimens reported Safe Safety SARS-CoV-2 variants second dose spike Standard dose Study participants systemic adverse reaction T-cell Response the SARS-CoV-2 undetectable vaccination Vaccine vaccine immunogenicity vaccine safety. [DOI] 10.3389/fimmu.2022.1010835 PMC 바로가기
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimensArticle Published on 2022-10-032022-11-15 Journal: The Journal of Experimental Medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] analysis antibody binding affinity biochemical breadth Cell ChAdOx1 ChAdOx1 vaccine Combination combinations COVID-19 vaccination COVID-19 vaccine effort elicited epitope exhibited Immunity intervals magnitude maturation memory B memory B cell monoclonal antibody mRNA Neutralizing neutralizing antibody regimen regimens response resulting SARS-CoV-2 SARS-CoV-2 pandemic significant difference specificity vaccination Vaccine viral variant while Wuhan-Hu-1 [DOI] 10.1084/jem.20220826 PMC 바로가기
Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicityArticle Published on 2022-10-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-receptor-binding domain antibody Antibody titer binding antibody BNT162b2 booster dose ChAdOx1 comparable COVID-19 delta variant domain dose enrolled evaluated geometric geometric mean titer group groups HCW HCWs healthcare worker Heterologous heterologous vaccination homologous humoral immune response Humoral response immunogenicity induce Local Neutralizing antibody response Neutralizing antibody titer participant RBD reactogenicity reactogenicity profile reduced robust SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2. significantly higher systemic reactogenicity tolerable vaccination variant wild-type SARS-CoV-2 [DOI] 10.1016/j.cmi.2022.04.019 PMC 바로가기
Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipientsArticle Published on 2022-10-012022-11-15 Journal: Hepatology communications [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Analysis analyzed Anti-spike anti-Spike IgG Antibody Response AstraZeneca BBIBP-CorV BMI booster response ChAdOx1 Clinical data collected Combination Concentration Control coronavirus correlation different dose dose evaluate evaluated Future groups healthy volunteer Heterologous homologous humoral IgG immunized Immunoglobulin inactivated information liver LTR LTRs Messenger RNA MMF neutralizing antibody nucleocapsid protein Odds ratio positive positive serology Probability prospective cohort study R 2 receiving recipient reduced reduction regimen reported RNA SARS-CoV-2 SARS-CoV-2 anti-spike IgG Serious Adverse Event Side effects significant difference significantly significantly higher Sinopharm Vaccine vaccine dose vaccine platform [DOI] 10.1002/hep4.2034 PMC 바로가기
Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign진행중인 전국적인 대규모 예방접종 캠페인에서 COVID-19 사망 및 중증 질환에 대한 예방접종의 비교 효과 및 지속성Article Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] 95% confidence interval Active surveillance acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S adjusted age all age groups approved BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 Cohort Cohort studies Comparative coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccines death dose doses Effectiveness effort immunogenicity intubation mass vaccination morbidity Mortality mRNA mRNA-1273 National of BNT162b2 offer offered pandemic prevented reduce registry data remained SARS-CoV-2 severe disease study period vaccinate vaccination Vaccine vaccine effectiveness. variant variants waned were used [DOI] 10.1002/jmv.27934 PMC 바로가기 [Article Type] Article
MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literatureArticle Published on 2022-10-012022-11-15 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome Adults affected analysed antibody AstraZeneca attack available data AZD1222 blindness BNT162b2 booster vaccination Brain Brainstem Brainstem encephalitis Case report cerebrospinal fluid ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1-S CNS complete recovery coronavirus Coronavirus disease 2019 Coronavirus disease 2019 (COVID-2019) COVID-19 CSF detectable disease dysfunction Encephalitis epidemiological Escalation exceeded female first dose functional glycoprotein IgG1 immunization Immunoglobulin Immunotherapy laboratory feature Longitudinally extensive transverse myelitis (LETM) majority male median median age median interval MOG MOG antibodies (MOG-IgG) mRNA vaccine mRNA-1273 mRNA-1273. much lower Myelin Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM) Myelitis Neuromyelitis Optica Neuromyelitis optica spectrum disorders occur occurred Optic Optic neuritis Oxford paraplegia Patient patients patients with SARS-CoV-2 Pfizer phenotype plasma Postinfectious Postvaccinal predominant radiological remained required residual symptom SARS-CoV2 serum Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) severity steroid treatment therapy Treatment Treatment outcome vaccination Vaccine WCC white cell [DOI] 10.1007/s00415-022-11194-9 PMC 바로가기
Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concernArticle Published on 2022-09-292022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] addition AstraZeneca Beta booster booster dose CD4 CD4+ CD8+ central memory ChAdOx1 Concentration COVID-19 COVID-19 vaccine Delta evaluated follicular highest homologous IFN-gamma IgG IgG antibody IgG isotype IL-17 Immune escape immunogenic immunogenicity induce memory mice mice immunization neutralizing antibody Neutralizing antibody titer new SARS-CoV-2 performed Population populations Protein S protein SARS-CoV-2 SARS-CoV-2 S protein SARS-CoV-2 variant SARS-CoV-2 variants significantly higher spike trimer spike trimeric protein T cells tested trimeric Trimeric spike protein Vaccine vaccine candidate vaccine candidate. Vaccines variant variants viral variant virus viruses VoC Wuhan [DOI] 10.3389/fimmu.2022.1020159 PMC 바로가기